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Renal cell carcinoma is often characterized by the presence of metachronous metastases in unusual sites. The
presence of isolated metastases is treated with surgical excision with good anticipated results. On the other hand,
systemic chemotherapy is administered in the context of metastatic spread, usually sunitib or sorafenib. In such
cases, however, the presence of symptomatic foci calls for minimal intervention.
We present a case of a 77-year-old patient who presented with obstructive jaundice due to an ampullary mass.
Endoscopic excision and biopsy set the diagnosis of metastatic renal cell carcinoma. Consequently, imaging studies
revealed the presence of multiple foci in the lungs and bone. Therefore, pancreatoduodenectomy was excluded
and the patient underwent endoscopic ampullectomy and was set to oral sunitinib. Interestingly, despite
generalized spread, local control was achieved until the patient succumbed to carcinomatosis.
Painless obstructive jaundice in a patient with history of renal cancer and negative computed tomography scanning
for pancreatic or other causes of obstruction should alert for prompt investigation for an ampullary metastasis.Background
Obstructive jaundice is one of the most typical clinical
signs caused by inflammation, gallstones or tumors of
the periampullary region. Painless and progressive rise of
serum bilirubin, however, is mostly attributed to tumori-
genic entities, rather than inflammatory processes.
Case presentation
A 77-year-old male presented with painless obstructive
jaundice. He had a history of right nephrectomy for a
T2N0M0 renal clear cell carcinoma 3 years ago. Ultrasound
and abdominal computed tomography (CT) scanning
depicted the common bile duct dilated up to its distal end.
Endoscopic retrograde cholangiopancreatography (ERCP)
revealed an ampullary tumor (Figure 1). Consequently,
ampullectomy with endoscopic sphincterotomy and
placement of a plastic 10 Fr biliary stent were performed
(Figure 2A).
Histology showed a clear cell carcinoma, consistent with
renal origin. Immunochemistry confirmed the diagnosis
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revealed the presence of lung and bone metastases. The
presence of multiple metastatic foci excluded the need
for pancreatoduodenectomy and the patient was treated
with oral sunitinib. For better palliation, repeat ERCP
was performed a month later and additional excision of
remnant tissue was performed in combination with argon
plasma coagulation (APC) and placement of a partially
covered metallic biliary stent (Wallstent; Boston Scientific,
Natick, MA) (Figure 2B). Six months later the stent was
removed and multiple biopsies showed no evidence of
residual tumor (Figure 3). The patient was re-evaluated
with endoscopy every 6 months. The patient succumbed
to metastatic disease 1.5 years later without jaundice or
abnormal liver function tests.Conclusion
Renal cancer counts approximately for 3.8% of all adult
malignancies [1]. The treatment for localized disease is
radical nephrectomy, despite the fact that recent data
suggest that less extended procedures in selected patients,
such as nephron-sparing surgery (partial nephrectomy) as
well as laparoscopic procedures, hold the same results in
terms of survival rate [2-6]. Surgical excision is consideredntral Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Figure 1 The ampullary mass depicted in endoscopy. Figure 3 Endoscopic image of the papilla 6 months after
treatment, depicting good local control of the lesion.
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(pathologic stage pT1-2), whereas 5-year cancer-specific
survival rates after nephrectomy decrease to 20 to 53% for
patients with locally advanced tumors and below 15% for
patients with metastatic disease [7]. Respectively, the rate
of recurrence, even in cases of resection with curative
intent, is high, ranging from 20 to 30%. It is estimated
that, in total, 50% of the patients with renal carcinoma will
present with or eventually develop metastatic disease [8].
Adjuvant therapy consisting of IL-2 and IFN-a, which wasFigure 2 (A) Image of the ampulla after ampullectomy, endoscopic sp
Post ampullectomy endoscopy (B) The papilla after additional excision of r
placement of a partially covered metallic biliary stent, 1 month after the in
coagulation and metallic stent placement.considered the standard of care for many years, held very
low response rates. Recent advances in our understanding
of the biology of renal cell carcinoma led to the devel-
opment of novel targeted therapies such as mTOR
(mammalian target of rapamycin) inhibitors as temsirolimus
or the inhibitors of the split-kinase-domain family of recep-
tors of tyrosine kinase sunitinib and sorafenib, which pre-
vent tumor angiogenesis through vascular endothelial
growth factor inhibition (mTOR and VEGF are commonlyhincterotomy and the placement of a plastic 10 Fr biliary stent.
emnant tissue in combination with argon plasma coagulation and
itial intervention. One month later, additional argon plasma
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rates are currently under investigation in trials; sunitinib,
however, has been established as first-line treatment for
advanced renal cell carcinoma (RCC) [9]. Usual sites of
metastatic spread are the liver, the lungs, the brain and
the bones, whereas less common sites are the gallblad-
der and the urinary bladder. Metastases usually occur in
the first 3 years after nephrectomy. However, metastatic
foci from renal cancer have been reported as late as 25
years after radical nephrectomy which was considered
curative [10].
Ampullary metastases from RCC are quite rare. Sporadic
reports of isolated metastases in the ampulla of Vater
involved lesions which presented with obstructive jaun-
dice [11], malabsorption [12] or obscure gastrointestinal
bleeding, with the prevailing mode of spread being the
hematogenous route [13]. Diagnosis is usually set by
endoscopic biopsy, since cross-sectional imaging may often
fail to delineate a lesion. The treatment proposed for
isolated lesions is pancreatoduodenectomy, since data
demonstrate sufficient median survival (26 months)
and an actuarial 5-year survival of 75%. It is important
to denote that, out of the tumors that metastasize in
the pancreas and the periampullary region, renal cancer
yields the most favorable prognosis; therefore surgical
excision is advocated in cases of isolated foci [14-16].
However, this operative approach is not indicated in the
presence of multiple metastatic foci and such patients
are treated with systematic chemotherapy. The therapeutic
challenge is the presence of subsequent complications due
to the presence of an ampullary lesion such as in our case,
in which intervention was mandatory for the relief of
obstructive jaundice. The efficacy of endoscopic resection
for benign lesions of the ampulla has been proven [17,18]
and has been advocated for small tumors in high-risk
patients as a low-risk, minimally invasive procedure [19].
Tumor-free margin can be obtained despite the fact that
there had been past reports of local recurrence up to 26%
when endoscopic snare excision was utilized [20], since
techniques such as APC mitigate such concerns [21]. It is
clear that limitations to the efficacy of the method, such as
the size of the lesion (larger than 50 mm) and the imaging
features in the endoscopic ultrasound or intraductal ultra-
sound [22], do not apply strictly when the procedure is
palliative, such as in our case. It is evident that the ideal
result would be ampullectomy with clear resection margins,
but the aid of fulgurating techniques such as APC may
provide equal results. In our patient, local control was
achieved until he succumbed. It seems that in the hands
of an experienced endoscopist, endoscopic ampullectomy is
a safe and effective procedure in order to provide palliation
from metastatic foci in patients with disseminated disease,
as well as in high-risk patients who are not candidates for
pancreatoduodenectomy.Keypoints for successful outcome are negative resection
margins and endoscopic surveillance [23], but primarily
clinical suspicion that the presence of painless jaundice in a
patient with history of renal cancer and negative CT scan-
ning for pancreatic or other causes of obstruction should
alert for prompt investigation for an ampullary metastasis.
Consent
Written informed consent was obtained from the next of
kin of the patient for publication of this Case report and
any accompanying images. A copy of the written consent is
available for review by the Editor-in-Chief of this journal.
Abbreviations
APC: Argon plasma coagulation; CT: Computed tomography;
ERCP: Endoscopic retrograde cholangiopancreatography; IFN: Interferon;
IL: Interleukin; RCC: Renal cell carcinoma.
Competing interests
The authors declare that they have no competing interests.
Author's contributions
AV and AP performed endoscopy and reviewed the images. EK collected the
data. AK, CS and GPF reviewed literature,drafted and wrote the manuscript.
All authors read and approved the final manuscript.
Author details
12nd Department of Surgery, Aretaieion Hospital, Medical School, National
and Kapodistrian, University of Athens, Athens, Greece. 21st Department of
Anesthesiology, Aretaieion Hospital, Medical School, National and
Kapodistrian, University of Athens, Athens, Greece. 3Department of
Pathology, Aretaieion Hospital, Medical School, National and Kapodistrian,
University of Athens, Athens, Greece.
Received: 7 February 2013 Accepted: 19 September 2013
Published: 7 October 2013
References
1. Jemal A, Siegel R, Xu J, Ward E: Cancer statistics. CA Cancer J Clin 2010,
60:277–300.
2. Clayman RV, Kavoussi LR, Soper NJ, Dierks SM, Meretyk S, Darcy MD, Roemer
FD, Pingleton ED, Thomson PG, Long SR: Laparoscopic nephrectomy:
initial case report. J Urol 1991, 146:278–282.
3. Portis AJ, Yan Y, Landman J, Chen C, Barrett PH, Fentie DD, Ono Y,
McDougall EM, Clayman RV: Long-term follow up after laparoscopic
radical nephrectomy. J Urol 2002, 167:1257–1262.
4. Lau WK, Blute ML, Weaver AL, Torres VE, Zincke H: Matched comparison of
radical nephrectomy vs nephron-sparing surgery in patients with
unilateral renal cell carcinoma and a normal contralateral kidney.
Mayo Clin Proc 2000, 75:1236–1242.
5. Uzzo RG, Novick AC: Nephron sparing surgery for renal tumors:
indications, techniques and outcomes. J Urol 2001, 166:6–18.
6. Hafez KS, Novick AC, Campbell SC: Patterns of tumor recurrence and
guidelines for follow up after nephron sparing surgery for sporadic renal
cell carcinoma. J Urol 1997, 157:2067–2070.
7. Zisman A, Pantuck AJ, Dorey F, Chao DH, Gitlitz BJ, Moldawer N, Lazarovici
D, de Kernion JB, Figlin RA, Belldegrun AS: Mathematical model to predict
individual survival for patients with renal cell carcinoma. J Clin Oncol
2002, 20:1368–1374.
8. Janzen NK, Kim HL, Figlin RA, Belldegrun AS: Surveillance after radical or
partial nephrectomy for localized renal cell carcinoma and management
of recurrent disease. Urol Clin North Am 2003, 30(4):843–852.
9. Najjar YG, Rini BI: Novel agents in renal carcinoma: a reality check.
Ther Adv Med Oncol 2012, 4(4):183–194.
10. Shiono S, Yoshida J, Nishimura M, Nitadori J, Ishii G, Nishiwaki Y, Nagai K:
Late pulmonary metastasis of renal cell carcinoma resected 25 years
after nephrectomy. Jpn J Clin Oncol 2004, 34:46–49.
Karakatsanis et al. World Journal of Surgical Oncology 2013, 11:262 Page 4 of 4
http://www.wjso.com/content/11/1/26211. Bolkier M, Ginesin Y, Moskovitz B, Munichor M, Levin DR: Obstructive jaundice
caused by metastatic renal cell carcinoma. Eur Urol 1991, 19(1):87–88.
12. McKenna JI, Kozarek RA: Metastatic hypernephroma to the ampulla of
Vater: an unusual cause of malabsorption diagnosed at endoscopic
sphincterotomy. Am J Gastroenterol 1989, 84:81–83.
13. Janzen RM, Ramj AS, Flint JD, Scudamore CH, Yoshida EM: Obscure
gastrointestinal bleeding from an ampullary tumour in a patient with a
remote history of renal cell carcinoma: a diagnostic conundrum.
Can J Gastroenterol 1998, 12:75–78.
14. Le Borgne J, Partensky C, Glemain P, Dupas B, de Kerviller B:
Pancreaticoduodenectomy for metastatic ampullary and pancreatic
tumors. Hepatogastroenterology 2000, 47:540–544.
15. Sohn TA, Yeo CJ, Cameron JL, Nakeeb A, Lillemoe KD: Renal cell carcinoma
metastatic to the pancreas: results of surgical management. J Gastrointest
Surg 2001, 5:346–351.
16. Machado NO, Chopra P: Pancreatic metastasis from renal cell
carcinoma managed by Whipple’s resection. A case report and
literature review of metastatic pattern, surgical management and
outcome. JOP 2009, 6(10):413–418.
17. Katsinelos P, Paroutoglou G, Kountouras J, Beltsis A, Papaziogas B, Mimidis K,
Zavos C, Dimiropoulos S: Safety and long-term follow-up of endoscopic
snare excision of ampullary adenomas. Surg Endosc 2006, 20:608–613.
18. Catalano MF, Linder JD, Chak A, Sivak MV Jr, Raijman I, Geenen JE, Howell
DA: Endoscopic management of adenoma of the major duodenal
papilla. Gastrointest Endosc 2004, 59:225–232.
19. Hoyuela C, Cugat E, Veloso E, Marco C: Treatment options for villous adenoma
of the ampulla of Vater. HPB Surg 2000, 11:325–330. discussion 330–331.
20. Shemesh E, Nass S, Czerniak A: Endoscopic sphincterotomy and
endoscopic fulguration in the management of adenoma of the papilla
of Vater. Surg Gynecol Obstet 1989, 169:445–448.
21. Patel R, Varadarajulu S, Wilcox CM: Endoscopic ampullectomy: techniques
and outcomes. J Clin Gastroenterol 2012, 46:8–15.
22. Boix J, Lorenzo-Zúñiga V, Moreno dVV, Domènech E, Gassull MA:
Endoscopic resection of ampullary tumors: 12-year review of 21 cases.
Surg Endosc 2009, 23:45–49.
23. Bellizzi AM, Kahaleh M, Stelow EB: The assessment of specimens procured
by endoscopic ampullectomy. Am J Clin Pathol 2009, 132:506–513.
doi:10.1186/1477-7819-11-262
Cite this article as: Karakatsanis et al.: Obstructive jaundice due to
ampullary metastasis of renal cell carcinoma. World Journal of Surgical
Oncology 2013 11:262.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
